Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly And Investors Spin Out Xigris To Form New Critical Care Company BioCritica

This article was originally published in The Pink Sheet Daily

Executive Summary

Initial focus of the private biotech will be on continued development and commercialization of Xigris for sepsis; investment backers are NovaQuest Capital and Care Capital.

You may also be interested in...



Xigris Withdrawal’s Impact On Lilly Is Minimal, But Leaves BioCritica Pondering Its Future

Key business questions linger following Eli Lilly & Co.’s announcement on Oct. 25 that it is withdrawing its troubled sepsis drug Xigris from all markets: What’s the impact of the action on Lilly, and what’s next for BioCritica Inc., the start-up formed largely to take over the drug’s commercialization?

Xigris Withdrawal’s Impact On Lilly Is Minimal, But Leaves BioCritica Pondering Its Future

Key business questions linger following Eli Lilly & Co.’s announcement on Oct. 25 that it is withdrawing its troubled sepsis drug Xigris from all markets: What’s the impact of the action on Lilly, and what’s next for BioCritica Inc., the start-up formed largely to take over the drug’s commercialization?

The Long Goodbye: Lilly Finally Kicks Troubled Sepsis Drug Xigris To The Curb

Eli Lilly & Co. announced Oct. 25 that it is ending its ten-year relationship with Xigris, withdrawing the sepsis drug from all markets and ceasing further clinical trials.

Related Content

Topics

UsernamePublicRestriction

Register

PS072276

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel